{"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% confidence interval for the time to treatment failure could not be estimated due to too few treatment failures.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"The time from the date of registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal. If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they were removed from treatment. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","populationDescription":"All enrolled patients who began treatment were evaluated for safety and response.","reportingStatus":"POSTED","timeFrame":"From baseline to end of active treatment","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"months"}